Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2018-03-09 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Regulatory Filings Classification · 95% confidence The document is a monthly disclosure required by the AMF (Autorité des Marchés Financiers) regarding the total number of voting rights and shares composing the share capital. This type of regulatory disclosure, which provides transparency on share capital structure, does not fit into specific categories like dividend announcements or director dealings, and is best classified as a general regulatory filing.
2018-03-09 French
Information relating to the total number of voting rights and shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and explicitly references Article 223-16 of the AMF General Regulations. It provides a table detailing the total number of shares and total voting rights as of a specific date (December 31, 2017). This content directly relates to the official disclosure of voting rights and share capital structure, which is a specific regulatory disclosure. Among the provided codes, none perfectly match a 'Monthly Voting Rights Disclosure'. However, the closest fit for a specific, recurring regulatory disclosure that isn't a major event (like M&A, dividend, or earnings) is often categorized under general regulatory announcements or specific capital structure updates. Since it deals with the total number of voting rights and shares, it is a specific type of capital/share information disclosure. Given the options, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most relevant category, as it concerns the official count of voting rights, even if this specific document is a monthly update rather than the final result of a meeting. If DVA is interpreted strictly as *results* of a vote, then 'Regulatory Filings' (RNS) would be the fallback. Given the explicit focus on 'voting rights' count, DVA is the primary candidate.
2018-03-09 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document title is "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of a specific date (February 28, 2018). This content directly relates to the structure of the share capital and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it is a mandatory disclosure regarding the capital base, or potentially a general regulatory filing (RNS). However, since it details the composition of the capital and voting rights, SHA is the most specific fit among the provided options, as it concerns the share structure.
2018-03-09 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is an announcement from Ipsen detailing the 18 posters that will be presented at the 15th Annual ENETS Conference. It lists specific research findings, drug names (lanreotide, cabozantinib, telotristat ethyl), and includes detailed safety information (Contraindications, Warnings, Adverse Reactions) for Somatuline and Cabometyx. This structure—announcing scientific data presentation at a conference, followed by detailed drug information—is characteristic of a press release or a scientific update, but it is not a formal regulatory filing like a 10-K, an Earnings Release (ER), or a comprehensive Interim Report (IR). Since it is an announcement about scientific data being presented at a medical conference, it most closely aligns with a general scientific or investor-related announcement. Given the options, it is not a standard financial report, a management change, or a specific regulatory filing. It functions as an Investor Presentation (IP) of scientific findings, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure, but the content is heavily focused on scientific data presentation. However, the document itself is a press release announcing scientific data presentation, which often falls under Investor Presentation (IP) or a general Regulatory Filing (RNS). Since it is a detailed announcement of scientific data to be presented, 'Investor Presentation' (IP) is a strong fit, as these often precede or accompany investor briefings. Given the context of a company announcing its scientific presence at a major conference, 'IP' (Investor Presentation) is the most appropriate classification for this type of scientific disclosure, even though it's formatted as a press release.
2018-03-06 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Ipsen dated March 6, 2018, announcing that they will present 18 posters at the 15th annual ENETS conference regarding their products (Lanreotide, Cabozantinib, Telotristat Ethyl) for neuroendocrine tumors (NETs). The text details the specific posters, the conference schedule, and provides safety/product information for Somatuline and Cabometyx. This content is characteristic of an announcement related to scientific data presentation at a medical conference, which falls under the scope of Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, given the focus on presenting scientific data and research findings to the investment/medical community, 'Investor Presentation' (IP) is the most fitting category, as these announcements often accompany or precede investor briefings on R&D progress. It is not a formal financial report (10-K, IR, ER) or a general regulatory announcement (RNS), but rather a specific communication about scientific milestones.
2018-03-06 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document text is a press release dated February 21, 2018, announcing a strategic agreement between Arix Bioscience and Ipsen to develop and commercialize innovative therapies. It details the terms of the collaboration, includes quotes from the CEOs, and provides boilerplate information about both companies. This type of announcement, detailing a significant business development or partnership, does not fit neatly into the specific financial reporting categories (like 10-K, IR, ER, or DIV). Since it is a formal announcement of a major business event, and it is not a transcript (CT), a proxy statement (PSI), or a management discussion (MDA), the most appropriate general category for a significant, non-standard corporate announcement is 'Regulatory Filings' (RNS), which serves as a broad category for material news releases that don't fit elsewhere, or potentially 'Capital/Financing Update' (CAP) if the deal involved significant capital structure changes, but the focus here is strategic partnership/development. Given the nature of the announcement (strategic deal), RNS is the best fit as a general material news release.
2018-02-21 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.